Fostamatinib Disodium Patent Expiration

Fostamatinib Disodium is Used for treating thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who had an insufficient response to previous treatment. It was first introduced by Rigel Pharmaceuticals Inc in its drug Tavalisse on Apr 17, 2018.


Fostamatinib Disodium Patents

Given below is the list of patents protecting Fostamatinib Disodium, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Tavalisse US7449458 Prodrugs of 2,4-pyrimidinediamine compounds and their uses Sep 04, 2031 Rigel Pharms Inc
Tavalisse US7538108 Prodrugs of 2,4-pyrimidinediamine compounds and their uses Mar 28, 2026 Rigel Pharms Inc
Tavalisse US7989448 Prodrugs of 2,4-pyrimidinediamine compounds and their uses Jun 12, 2026 Rigel Pharms Inc
Tavalisse US8163902 Prodrugs of 2,4-pyrimidinediamine compounds and their uses Jun 17, 2026 Rigel Pharms Inc
Tavalisse US8211889 Prodrugs of 2,4-pyrimidinediamine compounds and their uses Jan 19, 2026 Rigel Pharms Inc
Tavalisse US8263122 Wet granulation using a water sequestering agent Nov 24, 2030 Rigel Pharms Inc
Tavalisse US8445485 Prodrugs of 2,4-pyrimidinediamine compounds and their uses Jun 17, 2026 Rigel Pharms Inc
Tavalisse US8652492 Wet granulation using a water sequestering agent Nov 06, 2028 Rigel Pharms Inc
Tavalisse US8771648 (Trimethoxyphenylamino) pyrimidinyl formulations Jul 27, 2032 Rigel Pharms Inc
Tavalisse US8912170 Prodrugs of 2,4-pyrimidinediamine compounds and their uses Jun 17, 2026 Rigel Pharms Inc
Tavalisse US8951504 (trimethoxyphenylamino) pyrimidinyl formulations Jul 27, 2032 Rigel Pharms Inc
Tavalisse US9266912 Prodrugs of 2,4-pyrimidinediamine compounds and their uses Jan 19, 2026 Rigel Pharms Inc
Tavalisse US9283238 Prodrugs of 2,4-pyrimidinediamine compounds and their uses Jun 17, 2026 Rigel Pharms Inc
Tavalisse US9737554 Prodrugs of 2,4-pyrimidinediamine compounds and their uses Jan 19, 2026 Rigel Pharms Inc
Tavalisse USRE48898 Prodrugs of 2,4-pyrimidinediamine compounds and their uses Jan 19, 2026 Rigel Pharms Inc


Coming Soon

Patent Strength Analyzer

Let us know if you're excited!

🤩🥱

Thank you for your response 🥳